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ABSTRACT	 	Inflammation	is	a	complicated	problem	for	today’s	human	beings.	Large	numbers	of	people	have	been	diag-nosed	with	arthritis	along	with	inflammation.	This	is	beside	the	others	that	suffer	inflammation	caused	by	an	injury.	There	are	alternatives	that	can	be	considered	as	temporary	or	permanent	treatments	of	chronic	inflammatory	diseases.	Plants,	as	well	as	other	biological	resources,	are	most	welcomed	to	the	therapeutic	area.	Using	the	plants’	compounds	with	high	potential	as	novel	techniques	are	today’s	bio-pharmacologist	concern.	Bromelain	has	been	more	attractive	due	to	its	characteristics.	This	review	is	an	overview	of	anti-inflammatory	and	anti-cancer	effect	of	bromelain	as	a	confident	treatment	for	all	inflammatory	disease.	
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INTRODUCTION	Bromelain	is	a	type	of	proteolytic	enzyme	present	in	the	tissues	of	the	plant	family	Bromeliaceae,	of	which	pineapple	 is	 the	 best	 known	 source	 [1].	 Lesser	 size	presented	is	(EC	3.4.22.32)	with	23.8	kDa	thiol	pro-teinase	Bromelain	 is	 a	 combination	of	 various	 thiol	endo	 peptidases	 and	 other	 elements	 like	 phospha-tases,	glucosidase,	peroxidases,	cellulases,	glycopro-teins,	carbohydrates,	and	several	protease	inhibitors	[2].		The	enzymatic	activities	of	bromelain	comprise	a	wide	spectrum	with	pH	range	of	5.5	to	8.0	[3].	Differ-ent	protein	fractions	were	obtained	by	means	of	var-ious	“biochemical	techniques	as	sodium	dodecyl	sul-phate	 polyacrylamide	 gel	 electrophoresis”	 (SDS-
PAGE),	isoelectric	focusing	(IEF),	and	multicathodal-PAGE	 [4].	 Nowadays,	 bromelain	 is	 prepared	 from	cooled	pineapple	 juice	by	centrifugation,	ultrafiltra-tion,	and	lyophilization.	The	process	yields	a	yellow-ish	 powder,	 the	 enzyme	 activity	 of	 which	 is	 deter-mined	with	different	substrates	such	as	casein	 (FIP	unit),	 gelatin	 (gelatin	 digestion	 units),	 or	 chromo-genic	tripeptides	[5].	Bromelain	derived	from	stem	of	pineapple	(Ananas	comosus	L.	Merryl)	 [6],	may	offer	such	 an	 alternative	 for	 nonsteroidal	 anti-inflamma-tory	drugs	[7].	There	is	accumulating	evidence	show-ing	the	role	of	NF-kB	signaling	and	over-expression	in	many	types	of	cancers	 [8,9].	Emerging	evidences	also	suggest	that	depending	on	the	cell	context,	NF-kB	can	also	promote	tumor	suppression	[10].	Among	multiple	target	genes	of	NF-kB	is	Cox-2,	a	key	player	in	chronic	and	 cancer-related	 inflammation	 [11,12].	 Bromelain	was	shown	to	down-regulate	the	NF-kB	and	Cox-2	ex-pression	 in	mouse	 papillomas	 [13]	 and	 in	models	 of	skin	tumorigenesis	[14].	Additionally,	in	human	mono-cytic	leukemia	and	murine	microglial	cell	lines,	bro-melain	 was	 shown	 to	 inhibit	 bacterial	 endotoxin	(LPS)-induced	NF-jB	activity	as	well	as	the	expression	of	PGE2	and	Cox-2	[15,16].	
Absorption	and	Bioavailability	The	body	is	able	to	absorb	a	large	amount	of	brome-lain	(about	12	gm/day)	without	facing	any	major	neg-ative	effects.	Bromelain	is	absorbed	by	the	gastroin-testinal	tract	without	being	reduced	where	40%	of	la-belled	bromelain	can	be	absorbed	in	complex	molec-ular	form	[2].	Bromelain	was	found	to	hold	its	proteolytic	activity	in	plasma	and	was	also	found	to	link	to	the	alpha	2-mac-
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roglobulin	and	alpha1-antichymotrypsin,	the	two	an-tiproteinases	 of	 blood.	 In	 a	 recent	 research,	3.66mg/mL	of	bromelain	was	shown	to	be	stable	in	the	 artificial	 stomach	 juice	 after	 4	 hrs	 of	 reaction	while	2.44	mg/mL	of	bromelain	endured	in	the	artifi-cial	blood	after	4	hrs	of	reaction	[18].	
Medicinal	Uses	of	Bromelain	in	the	Body	Clinical	studies	have	shown	that	bromelain	can	help	in	the	treatment	of	several	disorders.	Bromelain	has	a	wide	range	of	applications	such	as	being	a	cleansing	agent,	meat	tenderizer,	a	digestive	aid,	and	an	anti-in-flammatory	agent.	The	year	of	2001	Maurer	was	the	
first	who	showed	characteristics	in	bromelain	as	a	fi-brinolytic	agent	and	an	antibiotic	potentiating	agent,	etc	[2].	These	enzymes	are	classified	according	to	their	inactivation	ability.	For	instance,	in	case	of	Ananain,	it	will	rapidly	become	inactivate	with	white	protein-ase	inhibitor	cystatin	of	chicken	egg	and	trans-epoxy-succinyl-l-leucylamido	(4-guanidino)	butane,	but	for	fruits,	it	will	happen	very	slowly	[4].	It	was	also	shown	through	in-vitro	experiments	that	bromelain	has	the	ability	 to	 control	 surface	 adhesion	 molecules	 on	 T	cells,	macrophages,	and	natural	killer	 cells	and	also	induce	the	secretion	of	IL-1,	IL-6,	and	tumour	necro-
Table 1: Cellular and molecular targets of bromelain related to its anti-inflammatory activity [17] 
 
The effects of bromelain are marked as follow:¯ decreased, ­increased = unchanged. 
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sis	 factor-α	 (TNF-α)	 by	 peripheral	 blood	 mononu-clear	cells	(PBMCs)	[19].	There	are	also	other	proven	benefits	 from	using	 bromelain.	 For	 example,	 it	was	found	that	oral	therapy	with	bromelain	produces	cer-tain	 analgesic	 and	 anti-inflammatory	 effects	 in	 pa-tients	with	rheumatoid	arthritis,	one	of	the	most	com-mon	 autoimmune	 diseases	 [20].	 In	 a	 multi-centre	study	 conducted	 in	 Germany,	 it	 was	 reported	 that	bromelain	produced	a	positive	outcome	compared	to	placebo	for	patients	with	arthritis	 [21].	 In	a	more	re-cent	study,	a	double	blinded	 trial	was	conducted	 to	compare	the	oral	enzyme	preparation	of	Phlogenzym	(containing	bromelain,	with	 trypsin	and	rutin)	with	an	 NSAID	 (diclofenac)	 during	 a	 3-week	 treatment	among	 73	 patients	 suffering	 osteoarthritis	 of	 the	knee	[22].	There	is	also	experimental	evidence	of	its	ef-fects	on	blood	coagulation	where	increases	in	the	se-rum	 fibrinolytic	 activity	 and	 prostaglandin	 levels	have	been	 recorded	due	 to	a	decrease	 in	PGE2	and	
thromboxane	A2.	Essentially,	this	phenomenon	is	im-portant	for	reducing	inflammation	[1].	The	role	of	the	analgesic	is	a	secondary	effect	on	factors	of	reducing	pain-inducing,	 contains	 immune	 complexes,	 debris,	and	oedema	[22].	Moreover,	for	cases	like	bradykinin	it	has	found	its	direct	influence	effect	on	pain	media-tors.	For	instance,	it	was	shown	when	bradykinin	was	used	 directly	 onto	 surgically	 denuded	 blisters,	 it	highly	reduced	pain	response	[23].	Statistics	studies	on	humans	and	some	animals	demonstrated	anti-inflam-matory	 effects	 of	 bromelain	 administration	 orally,	showing	 low	 levels	of	absorbance	after	oral	 admin-istration.	In	human,	the	plasma	level	 is	 less	than	10	mg/ml	by	treating	4	g/daily	 [23,	24].	This	will	happen	due	to	bromelain	inhibition	by	alpha-2-	macroglobu-lin	that	is	the	plasma	proteinase	inhibitor	[25].	It	was	also	concluded	based	on	existing	proofs	that	brome-lain	 can	 be	 a	 promising	 candidate	 for	 the	 develop-
Table 2: Established mechanisms of anti-inflammatory and anti-cancer activity of bromelain and future re-
search directions [2] 
Established mechanisms Research directions 
Inhibition of tumor cell growth and metastasis 
Stimulation of apoptosis activators and inhibition of cell sur-
vival activators in tumor cells 
Bromelain effects on cell survival and 
apoptosis regulators in human cancer cell 
lines and primary cells 
Cleavage of CD44 Bromelain effect on tumor markers of adhe-sion and invasion 
Regulation of inflammatory mediators 
Inhibition of NF-kB/Cox-2/PGE2 expression in tumor cells 
Regulation of inflammatory cytokines and growth factors 
(TNF-α, IL-1β, IL-6 and IFNγ) 
Bromelain effect on TNF-α, IL-1β, IL-6 
and IFNγ in cancer patients-derived im-
mune cells 
Regulation of AGE mediated pathways 
Bromelain effect on RAGE expression in 
cancer cells; Bromelain-RAGE mediated 
effect on NF-kB 
Immuno-modulatory activity 
CD44-mediated activation of lymphocytes Bromelain effect on CD44-mediated activa-tion of cancer patient-derived lymphocytes 
CD25-mediated modulation of T lymphocytes activity 
Bromelain effect on CD25-dependent re-
sponse of cancer patient-derived lympho-
cytes 
Stimulation of neutrophils Bromelain effect on ROS production in cancer patients-derived neutrophils 
Stimulation of monocytic cytotoxicity Down-regulation of im-
mune system inhibitor (TGFb) 
Bromelain effect on TGFb and IL-10 ex-
pression in cancer cells 
Induction of antibodies that cross-react with cancer-expressed 
targets 
Analysis of human anti-cancer targets of 
anti-bromelain antibodies 
Alteration of tumor micro-environment 
Reduction of immune cells infiltration Bromelain effect on tumor infiltrate in hu-man cancers 
Changing profile of secreted mediators (chemokines) Bromelain effect on chemokine and chemo-kine receptors expression in tumor cells 
Regulation of haemostatic system 
Inhibition of platelets activation and aggregation Bromelain effect on cancer patients-derived platelet activation and aggregation 
Reduction of blood coagulation capacity Bromelain effect on coagulation parameters of cancer patients-derived blood 
Reduction of elevated levels of soluble fibrin Fibrinolytic ‘un-coating’ tumor cells and exposing them to immuno-editing 
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ment	of	future	oral	enzyme	therapies	for	oncology	pa-tients.	This	is	so	because	bromelain	is	able	to	be	ab-sorbed	in	human	intestines	without	degradation	and	loss	of	its	biological	activity	[17].	There	are	documents	that	 prove	 the	 proteolytical	 property	 of	 bromelain	will	cause	to	the	removing	of	some	cells	that	affects	the	migration	of	lymphocytes	and	their	activity	[7].	In	the	case	of	humans,	there	are	some	significant	exam-ples	like	collagen	or	adjuvant-induced	arthritis	[26],	Ig	Emediated	 perennial	 allergic	 rhinitis	 [27],	 experi-mental	 allergic	 encephalomyelitis	 (EAE),	 autoim-mune	disease	multiple	sclerosis	[28]	and	also	some	hu-man	 rheumatologic	 diseases	 [29].	 These	 findings	demonstrated	 that	 the	 concentration	 of	 bromelain	systemically	 delivered	 to	 affect	 cell	 surface	 brome-lain-sensitive	 molecules	 should	 be	 more	 than	 the	time	it	delivers	topically	[2].	Therefore,	in	the	case	of	IBD,	we	conclude	that	 the	anti-inflammatory	effects	of	bromelain,	orally	used,	are	similar	to	the	local	pro-teolytic	activity	of	intestinal	lumen,	then	systemic	ac-tivity.	Based	on	the	reports,	almost	three-quarters	of	bromelain-administered	patients	have	reported	com-plete	or	close	to	full	reduction	of	swelling	effect	with	a	reduction	in	soreness	and	pain.	Meanwhile,	small-scale	 studies	 have	 demonstrated	 anti-inflammatory	effects	of	bromelain	for	ulcerative	colitis	[23]	and	also	urogenital	tract	[30].	
CONCLUSION	As	mentioned,	detailed,	 the	 role	of	bromelain	as	an	anti-inflammatory	and	anti-cancer	agent	is	thought	to	be	multifaceted.	Bromelain	has	been	suggested	as	an	adjuvant	 therapeutic	 treatment	 for	 diseases	 which	are	 chronic	 inflammatory,	 malignant,	 and	 autoim-mune.	
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